Learn About Insulinoma

What is the definition of Insulinoma?

An insulinoma is a tumor in the pancreas that produces too much insulin.

Save information for later
Sign Up
What are the alternative names for Insulinoma?

Insulinoma; Islet cell adenoma, Pancreatic neuroendocrine tumor; Hypoglycemia - insulinoma

What are the causes of Insulinoma?

The pancreas is an organ in the abdomen. The pancreas makes several enzymes and hormones, including the hormone insulin. Insulin's job is to reduce the level of sugar (glucose) in the blood by helping sugar move into cells.

Most of the time when your blood sugar level decreases, the pancreas stops making insulin to make sure that your blood sugar stays in the normal range. Tumors of the pancreas that produce too much insulin are called insulinomas. Insulinomas keep making insulin, and can make your blood sugar level too low (hypoglycemia).

A high blood insulin level causes a low blood sugar level (hypoglycemia). Hypoglycemia may be mild, leading to symptoms such as anxiety and hunger. Or it can be severe, leading to seizures, coma, and even death.

Insulinomas are very rare tumors. They usually occur as single, small tumors. But there can also be several small tumors.

Most insulinomas are non-cancerous (benign) tumors. People with certain genetic disorders, such as multiple endocrine neoplasia type I, are at higher risk for insulinomas.

What are the symptoms of Insulinoma?

Symptoms are most common when you are fasting or skip or delay a meal. Symptoms may include:

  • Anxiety, behavior changes, or confusion
  • Clouded vision
  • Loss of consciousness or coma
  • Convulsions or tremor
  • Dizziness or headache
  • Hunger between meals; weight gain is common
  • Fast heart rate or palpitations
  • Sweating
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Insulinoma?

Surgery is the usual treatment for insulinoma. If there is a single tumor, it will be removed. If there are many tumors, part of the pancreas will need to be removed. At least 15% of the pancreas must be left to produce normal levels of enzymes for digestion.

In rare cases, the entire pancreas is removed if there are many insulinomas or they continue to come back. Removing the entire pancreas leads to diabetes because there is no longer any insulin being produced. Insulin shots (injections) are then required.

If no tumor is found during surgery, or if you can't have surgery, you may get the medicine diazoxide to lower insulin production and prevent hypoglycemia. A water pill (diuretic) is given with this medicine to prevent the body from retaining fluid. Octreotide is another medicine that is used to reduce insulin release in some people.

Who are the top Insulinoma Local Doctors?
Learn about our expert tiers
Learn more
What is the outlook (prognosis) for Insulinoma?

In most cases, the tumor is non-cancerous (benign), and surgery can cure the disease. But a severe hypoglycemic reaction or the spread of a cancerous tumor to other organs can be life-threatening.

What are the possible complications of Insulinoma?

Complications may include:

  • Severe hypoglycemic reaction
  • Spread of a cancerous tumor (metastasis)
  • Diabetes if the entire pancreas is removed (rare), or food not being absorbed if too much of the pancreas is removed
  • Inflammation and swelling of the pancreas
When should I contact a medical professional for Insulinoma?

Call your health care provider if you develop any symptoms of insulinoma. Seizures and losing consciousness are an emergency. Call 911 or the local emergency number right away.

Endocrine glands
Food and insulin release
What are the latest Insulinoma Clinical Trials?
Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients

Summary: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs. This study proposes 68Gallium(68Ga)-DOTATOC positron emission ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective Randomized Study of the Efficacy and Safety of 177Lu-DOTATOC With Either Standard or Personalized Dosing for the Treatment of Patients With Somatostatin Receptor Positive NETs

Summary: This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, seria...

What are the Latest Advances for Insulinoma?
Laparoscopic Enucleation of Pancreatic Neoplasms: A Single-Center Experience and Outcomes.
Practical Clinical Applications of Islet Autoantibody Testing in Type 1 Diabetes.
Tired of the same old research?
Check Latest Advances
Case Report: Insulinoma Presenting as Excessive Daytime Somnolence.
Who are the sources who wrote this article ?

Published Date: August 29, 2020
Published By: Brent Wisse, MD, board certified in Metabolism/Endocrinology, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Asban A, Patel AJ, Reddy S, Wang T, Balentine CJ, Chen H. Cancer of the endocrine system. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 68.

National Comprehensive Cancer Network website. NCCN clinical practice guidelines in oncology (NCCN guidelines): Neuroendocrine and adrenal tumors. Version 2.2020. www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Updated July 24, 2020. Accessed November 11, 2020.

Strosberg JR, Al-Toubah T. Neuroendocrine tumors. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 34.